ISRCTN62305334进行中（未招募）未知
Dynamic susceptibility contrast MRI Perfusion assessment of brain metastases: baseline characteristics and the study of pattern of perfusion change in suspected radionecrosis post-stereotactic radiosurgery (STARBEAM-X)
ewcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 40 人开始时间: 2023年2月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age of 18 years or above on the day of recruitment
- •2. Have one or more brain metastases from an extracranial primary solid malignancy
- •3. Accepted for stereotactic radiosurgery to one or more brain metastases following discussion at the local SRS MDT
- •4. Must have never received any form of prior radiotherapy to the brain
排除标准
- •1. Age < 18 years old at the time of eligibility screening
- •2. Patient has received prior radiotherapy to the brain
研究者
相似试验
已完成
2 期
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-alpha in patients with advanced renal cell carcinomaAdvanced or metastatic renal cell carcinomaMalignant neoplasm of kidney, except renal pelvisCancerISRCTN08193901East and North Hertfordshire NHS Trust (UK)30
尚未招募
不适用
Variability of dynamic contrast-enhanced MRI in the pituitary adenoma: Prospective comparison between gadobutrol and meglumine gadoterate usageKCT0006668Seoul National University Bundang Hospital74
已完成
不适用
Dynamic Contrast Enhanced Magnetic Resonance Imaging Parameters after Radiotherapy for Bone Metastases in Patients with Hepatocellular Carcinoma : A Prospective StudyDiseases of the musculo-skeletal system and connective tissueKCT0004861Samsung Medical Center14
已完成
不适用
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Study for Biochemocal Failures after Radical ProstatectomyProstate cancerJPRN-UMIN000009823The University of Tokyo Hospital50
进行中（未招募）
1 期
Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-a in patients with advanced renal cell carcinoma. - DCE-MRI changes in tumour vaculature with Bevacizumab and Interferon in advanced RCCPreviously untreated metastatic (stage IV) or locally advanced (inoperable stage III), renal cell carcinomaMedDRA version: 9.1Level: HLTClassification code 10038408Term: Renal cell carcinomasEUCTR2008-006414-19-GBEast and North Hertfordhsire NHS Trust30